Alisha Charlton Sells 1,000 Shares of Pro-Dex, Inc. (NASDAQ:PDEX) Stock

Pro-Dex, Inc. (NASDAQ:PDEX - Get Free Report) CFO Alisha Charlton sold 1,000 shares of the stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $40.02, for a total transaction of $40,020.00. Following the completion of the sale, the chief financial officer now directly owns 15,339 shares of the company's stock, valued at $613,866.78. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Pro-Dex Stock Up 3.8 %

PDEX traded up $1.58 during trading hours on Friday, reaching $42.68. 14,828 shares of the stock traded hands, compared to its average volume of 13,698. Pro-Dex, Inc. has a fifty-two week low of $15.70 and a fifty-two week high of $46.50. The company has a market cap of $139.09 million, a price-to-earnings ratio of 27.71 and a beta of 0.39. The company has a debt-to-equity ratio of 0.36, a current ratio of 3.41 and a quick ratio of 1.94. The firm's fifty day simple moving average is $29.24 and its two-hundred day simple moving average is $22.72.

Pro-Dex (NASDAQ:PDEX - Get Free Report) last announced its earnings results on Thursday, September 5th. The medical instruments supplier reported $0.46 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.35 by $0.11. Pro-Dex had a return on equity of 16.74% and a net margin of 9.17%. The business had revenue of $15.03 million for the quarter. As a group, analysts forecast that Pro-Dex, Inc. will post 1.42 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on PDEX shares. Ascendiant Capital Markets upped their target price on Pro-Dex from $28.00 to $30.00 and gave the stock a "buy" rating in a research report on Monday, September 9th. StockNews.com upgraded Pro-Dex from a "buy" rating to a "strong-buy" rating in a report on Saturday, September 7th.

Hedge Funds Weigh In On Pro-Dex

Institutional investors have recently made changes to their positions in the business. Perritt Capital Management Inc. grew its stake in Pro-Dex by 43.3% in the first quarter. Perritt Capital Management Inc. now owns 6,000 shares of the medical instruments supplier's stock worth $106,000 after purchasing an additional 1,813 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in Pro-Dex by 7.9% during the 2nd quarter. Renaissance Technologies LLC now owns 12,240 shares of the medical instruments supplier's stock worth $240,000 after buying an additional 900 shares during the last quarter. Bard Associates Inc. grew its position in shares of Pro-Dex by 17.6% in the 3rd quarter. Bard Associates Inc. now owns 13,596 shares of the medical instruments supplier's stock worth $406,000 after acquiring an additional 2,031 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Pro-Dex by 5.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 63,036 shares of the medical instruments supplier's stock valued at $1,238,000 after acquiring an additional 3,067 shares during the last quarter. 15.28% of the stock is owned by institutional investors and hedge funds.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.